After all, the risk of recurrence in patients with ER-negative primary cancer is higher than that in ER-positive tumors.12 Because there are many subtypes of breast cancer based on ER, HER and PR status, we still need to determine the expression and role of GBP2 and Drp1 in additional cancer specimens to determine whether the role of GBP2 and Drp1 in metastasis and tumorigenesis is conserved in other breast cancer subtypes. This evidence concerns the gene GBP2 and breast carcinoma.